Duc H T, Kinsky R G, Voisin G A
Ann Immunol (Paris). 1977 Jan-Mar;128(1-2):19-20.
Allo-immune sera were prepared by injecting CBA mice with spleen or thymus cells, or by two consecutive skin grafts of A/Jax origin. When absorbed 6 to 8 times on glutaradahyde treated A/Jax red blood cells (RBC), these sera lost all their haemagglutinating activity (anti- "SD" antibodies, predominantly H-2D) While their cytotoxic activities on A/Jax lymphocytes (anti-LD antibodies, perdominantly Ia, H-2IC) were partially preserved. Antibodies (anti-"XD") eluted form A/Jax RBC treated with an 0.5 M NaCl--HCL glycincing activity of these preparations was tested using SaI (A/Jax) grafts in CBA mice. Our results suggest that SD antigens are the main target of the enhancing effect. Further results obtained with DBA/2 anti-EL4 (C57Bl/6) sera confirmed this interpretation. Experiments performed with anti-idiotype and anti-recognition structure sera using tumor allograft targets, did not reveal any clear cut effect. Their relevance in tumor enhancement appears therefore doubtful.
同种免疫血清通过给CBA小鼠注射脾脏或胸腺细胞,或通过连续两次移植A/Jax来源的皮肤来制备。当这些血清在经戊二醛处理的A/Jax红细胞(RBC)上吸收6至8次后,它们的所有血凝活性(抗“SD”抗体,主要是H-2D)丧失,而它们对A/Jax淋巴细胞的细胞毒性活性(抗-LD抗体,主要是Ia,H-2IC)部分保留。用0.5M NaCl-HCl从A/Jax RBC洗脱的抗体(抗“XD”),这些制剂的溶血活性用CBA小鼠中的SaI(A/Jax)移植进行测试。我们的结果表明SD抗原是增强作用的主要靶点。用DBA/2抗EL4(C57Bl/6)血清获得的进一步结果证实了这一解释。使用肿瘤同种异体移植靶标用抗独特型和抗识别结构血清进行的实验未显示任何明确的效果。因此它们在肿瘤增强中的相关性似乎值得怀疑。